Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

COMPUGROUP MEDICAL SOCIETAS EUROPAEA

(COP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CompuGroup Medical SE & Co. KGaA: Release of a capital market information

02/25/2021 | 03:09pm EDT

DGAP Post-admission Duties announcement: CompuGroup Medical SE & Co. KGaA / Disclosure pursuant to Article 5(1)(a) of Regulation (EU) No 596/2014 and Article 3(1) of Commission Delegated Regulation (EU) No 2016/1052
CompuGroup Medical SE & Co. KGaA: Release of a capital market information

25.02.2021 / 21:08
Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Launch of the Share Buy-Back Program

Koblenz, February 25, 2021 - The share buy-back program announced by CompuGroup Medical SE & Co. KGaA (the "Company") in the ad-hoc release of February 25, 2021 will be launched on February 26, 2021. The Company is making use of the authorization granted by the annual general meeting of May 15, 2019 to purchase treasury shares pursuant to section 71(1) no. 8 of the German Stock Corporation Act (Aktiengesetz) in order to buy back a maximum number of up to 500,000 shares of the Company (corresponding to approx. 0,93% of the Company's share capital) at a maximum purchase price (excluding transaction costs) of up to EUR 40,000,000.00 in total (the "Share Buy-Back Program").

The Share Buy-Back Program will be carried out by a credit institution. The credit institution will acquire the shares on the stock market and will decide on the timing of acquisitions independently of the Company and in accordance with the safe harbor provisions of Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 (Market Abuse Regulation) in conjunction with the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016. In addition, the purchase price per share (excluding transaction costs) paid must not exceed, or fall short of, the volume-weighted average price of the Company's share in XETRA (or a functionally comparable successor system replacing the XETRA system) trading on the Frankfurt Stock Exchange during the last five trading days before the acquisition date by more than 10%.

The acquired treasury shares in CompuGroup Medical SE & Co. KGaA are to be used for purposes permitted under the authorization granted by the annual general meeting of May 15, 2019, in particular for servicing the existing stock option plans of the Company as well as the utilization as acquisition currency.

The share buy-back via XETRA on the Frankfurt Stock Exchange will begin on February 26, 2021, 00:00 hrs (CET) and terminates at the end of April 30, 2021, 24:00 hrs (CEST). To the extent shares in CompuGroup Medical SE & Co. KGaA shall be bought back during a closed period within the meaning of Article 19(11) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014 or during a period in which CompuGroup Medical SE & Co. KGaA resolved to delay the disclosure of inside information in accordance with Article 17(4) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, CompuGroup Medical SE & Co. KGaA has appointed a credit institution for the execution of these buy-backs, which will make its decisions concerning the timing of the acquisitions of the shares in CompuGroup Medical SE & Co. KGaA - in compliance with contractual obligations - independently of, and without influence by, CompuGroup Medical SE & Co. KGaA in accordance with Article 4(2)(b) of Commission Delegated Regulation (EU) No 2016/1052 of March 8, 2016. CompuGroup Medical SE & Co. KGaA will not influence the decisions of the credit institution in this respect.

The Share Buy-Back Program will be carried out in accordance with the safe harbor provision pursuant to Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014 and the provisions of Commission Delegated Regulation (EU) 2016/1052 of March 8, 2016 and on the basis of the aforementioned authorization of the general meeting of CompuGroup Medical SE & Co. KGaA of May 15, 2019. CompuGroup Medical SE & Co. KGaA also imposed corresponding obligations on the credit institution appointed by the Company for purchasing shares in the Company.

The shares in CompuGroup Medical SE & Co. KGaA will be purchased at market prices in accordance with the conditions for trading pursuant to Article 3 of Commission Delegated Regulation (EU) 2016/1052 of March 8, 2016. In particular, the shares in CompuGroup Medical SE & Co. KGaA will not be purchased at a price higher than the higher of the price of the last independent trade or the highest current independent purchase bid on the trading venue where the purchase is carried out. In addition, CompuGroup Medical SE & Co. KGaA will not purchase on any trading day more than 25% of the average daily volume of the shares on the trading venue on which the purchase is carried out. The average daily volume of shares is calculated on the basis of the average daily volume traded during the 20 trading days preceding the relevant date of purchase.

The Share Buy-Back Program may be suspended and also resumed at any time, to the extent necessary and permitted by law.

Information on transactions relating to the Share Buy-Back Program will be adequately disclosed no later than by the end of the seventh trading day following the date of execution of such transactions in a detailed form and in an aggregated form. In addition, CompuGroup Medical SE & Co. KGaA will post the disclosed transactions on its website (www.cgm.com) and ensure that the information is kept available to the public for at least five years from the date of disclosure.

End

Disclaimer:

This publication contains forward-looking statements. These statements are based on the current views, expectations and assumptions of, and information available to, the management of CompuGroup Medical SE & Co. KGaA. Forward-looking statements do not provide a guarantee of the occurrence of future results and developments and involve known and unknown risks and uncertainties. Various factors may cause actual future results, developments or events to differ materially from those described in these statements. Neither CompuGroup Medical SE & Co. KGaA nor any other person assumes any responsibility whatsoever for the accuracy of the views expressed in this publication or the assumptions on which they are based. CompuGroup Medical SE & Co. KGaA assumes no obligation to update the forward-looking statements contained in this publication.

Koblenz, February 25, 2021

CompuGroup Medical SE & Co. KGaA
The general partner



25.02.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: CompuGroup Medical SE & Co. KGaA
Maria Trost 21
56070 Koblenz
Germany
Internet: www.cgm.com

 
End of News DGAP News Service

1171345  25.02.2021 

fncls.ssp?fn=show_t_gif&application_id=1171345&application_name=news&site_id=zonebourse_sftp

ę EQS 2021
All news about COMPUGROUP MEDICAL SOCIETAS EUROPAEA
09:24aCOMPUGROUP MEDICAL : Deutsche Bank gives a Buy rating
MD
07/22COMPUGROUP MEDICAL : KoCoBox MED+ obtains approval as an electronic health recor..
EQ
07/22CompuGroup Medical Receives Kocobox MED+ Obtains Approval as an Electronic He..
CI
07/19COMPUGROUP MEDICAL SE & CO. KGAA : Preliminary announcement of the publication o..
EQ
06/17COMPUGROUP MEDICAL SE & CO. KGAA : Release according to Article 40, Section 1 of..
EQ
06/14COMPUGROUP MEDICAL : Company Presentation June
PU
06/02COMPUGROUP MEDICAL : Receives a Sell rating from Baader Bank
MD
06/01CompuGroup Medical SE & Co. KGaA acquired Visus Health It Gmbh.
CI
05/21COMPUGROUP MEDICAL : Receives a Sell rating from Baader Bank
MD
05/20COMPUGROUP MEDICAL SE & CO. KGAA : Ex-dividend day for final dividend
FA
More news
Financials
Sales 2021 1 019 M 1 204 M 1 204 M
Net income 2021 79,5 M 93,9 M 93,9 M
Net Debt 2021 430 M 508 M 508 M
P/E ratio 2021 46,9x
Yield 2021 0,72%
Capitalization 3 677 M 4 343 M 4 343 M
EV / Sales 2021 4,03x
EV / Sales 2022 3,77x
Nbr of Employees 7 534
Free-Float 48,9%
Chart COMPUGROUP MEDICAL SOCIETAS EUROPAEA
Duration : Period :
CompuGroup Medical Societas Europaea Technical Analysis Chart | COP | DE0005437305 | MarketScreener
Technical analysis trends COMPUGROUP MEDICAL SOCIETAS EUROPAEA
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 69,25 €
Average target price 80,19 €
Spread / Average Target 15,8%
EPS Revisions
Managers and Directors
Dirk Woessner Chairman-Management Board & CEO
Michael Rauch Chief Financial Officer
Philipp von Ilberg Chairman-Supervisory Board
Frank Brecher Chief Technology Officer
Hannes Reichl Managing Director-Clinical & Social Care
Sector and Competitors
1st jan.Capi. (M$)
COMPUGROUP MEDICAL SOCIETAS EUROPAEA-11.90%4 192
ORACLE CORPORATION35.55%219 060
SAP SE9.87%165 786
INTUIT INC.39.12%132 829
SERVICENOW, INC.6.49%107 607
DOCUSIGN, INC.38.78%54 398